Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Lifestyle intervention and weight loss
8 evidence topics · 7 sources
EASL-EASD-EASO guideline recommendations: weight loss targets, diet quality, and physical activity in adults with MASLD
EASL-EASD-EASO guideline: achievement and maintenance of weight loss
AASLD practice guidance statements: caloric deficit and physical activity
“Thus, actionable statements rather than formal recommendations are provided herein.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with NAFLD who are overweight or obese should be prescribed a diet that leads to a caloric deficit. When possible, diets with limited carbohydrates and saturated fat and enriched with high fiber and unsaturated fats (eg, Mediterranean diet) should be encouraged due to their additional cardiovascular benefits” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with NAFLD should be strongly encouraged to increase their activity level to the extent possible. Individualized prescriptive exercise recommendations may increase sustainability and have benefits independent of weight loss” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AASLD practice guidance: magnitude of weight loss and its maintenance
“Weight loss of 3%–5% improves steatosis, but greater weight loss (> 10%) is generally required to improve NASH and fibrosis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Few patients (≤ 10%) achieve effective weight loss despite structured interventions at 1 year, and fewer than half of these maintain the weight lost 5 years after intervention” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Weight loss improves hepatic steatosis, NASH, and hepatic fibrosis in a dose-dependent manner.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ADA Standards of Care recommendation 4.25: lifestyle change in adults with type 2 diabetes or prediabetes and MASLD
“Adults with type 2 diabetes or prediabetes, particularly with overweight or obesity, who have metabolic dysfunction–associated steatotic liver disease (MASLD) should be recommended lifestyle changes using an interprofessional approach that promotes weight loss, ideally within a structured nutrition plan and physical activity program for cardiometabolic benefits B and histological improvement. C” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is consensus that a minimum weight loss goal of 5%, preferably ≥10%, is needed to improve liver histology” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individualized, structured weight loss and exercise programs offer greater benefit than standard counseling in people with MASLD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AASLD updates on resmetirom and semaglutide: lifestyle modification alongside pharmacotherapy
Weight loss and histology in biopsy-proven NASH: prospective cohort in Havana, Cuba, 293 participants, 261 with paired biopsies at week 52
“We conducted a prospective study of 293 patients with histologically proven NASH who were encouraged to adopt recommended lifestyle changes to reduce their weight over 52 weeks, from June 2009 through May 2013, at a tertiary medical center in Havana, Cuba.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Paired liver biopsies were available from 261 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week fifty-two, 88 subjects (30%) had lost ≥5% of their weight.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All patients who lost ≥10% of their weight had reductions NAS, 90% had resolution of NASH, and 45% had regression of fibrosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Intensive lifestyle intervention: randomized trial in 31 overweight or obese adults with biopsy-proven NASH, 48 weeks
“Thirty one overweight or obese individuals (Body mass index 25-40 kg/m2) with biopsy proven NASH were randomized in a 2:1 ratio to receive intensive lifestyle intervention (LS) or structured education (control).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After 48 weeks of intervention, participants assigned to LS lost an average of 9.3% of their weight vs 0.2% in the control group (p=0.003).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A higher proportion of participants in the LS group had a reduction of NAS ≥ 3 points or had post treatment NAS ≤ 2 as compared to the control group (72% vs 30%, p=0.03).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Post intervention liver biopsy was completed in 28/31 (90%) of participants, 18/21 (86%) in the lifestyle intervention group and 10/10 (100%) in the control group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote